Tag: Metastatic breast cancer

The FDA approved the first generic version of capecitabine in 2013, making this oral chemotherapy more accessible to patients with certain cancers. Knowing what is the generic for capecitabine can help individuals understand their medication options and potential cost savings during cancer treatment.

In the monarchE clinical trial for high-risk early breast cancer, adding Verzenio to hormone therapy for two years reduced the risk of cancer recurrence by 35% compared to hormone therapy alone [1.3.3]. This article explains how many years you can take Verzenio for based on your diagnosis.

Clinical trials show that correct administration of tucatinib is vital, with nearly everyone experiencing some side effects, including 22% reporting serious ones, emphasizing the need for patient education. Understanding **how is tucatinib administered** correctly is essential for maximizing its therapeutic benefits and ensuring patient safety throughout the treatment regimen.

First approved by the U.S. Food and Drug Administration (FDA) on January 7, 2005, for metastatic breast cancer, Abraxane (nab-paclitaxel) has been a key oncology medication for nearly two decades. Its longevity in the field is a testament to its innovative nanoparticle albumin-bound technology, which has addressed key limitations of its predecessor and expanded its use to treat multiple types of solid tumors.